

Supporting Information

Metallo- β -Lactamase Mediated Antimicrobial Resistance and Progress in Inhibitor Discovery

Author(s): Yongqiang Yang^{1,2,§}, Yu-Hang Yan^{3,§}, Christopher J. Schofield⁴, Alan McNally⁵, Zhiyong Zong^{1,2,6*}, Guo-Bo Li^{3*}

Author affiliations:

¹*Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China*

²*Center for Pathogen Research, Sichuan University, Chengdu, China*

³*Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University, Chengdu, China*

⁴*Department of Chemistry, Chemistry Research Laboratory and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, United Kingdom*

⁵*Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birmingham, Birmingham, United Kingdom*

⁶*Division of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, China*

[§]*Y. Yang and Y.-H. Yan are co-first authors.*

^{*}*E-mail: zongzhiy@scu.edu.cn; liguobo@scu.edu.cn*

Supplementary Table S1. Summary of discovered MBLs.

Acronym	Full name ^a	First report,		Variant no.	Intri./acq. ^c	RefSeq accession no.
		Year	Species ^b			
Subclass B1						
BclI	Beta-lactamase II	1966	<i>B. cereus</i>	6	I	NG_047222
CcrA	or —	1990	<i>B. fragilis</i>	18	A	NG_050389
CfiA						
IMP	imipenemase	1991	<i>P. aeruginosa</i>	91	A	NG_049172
BlaB	—	1998	<i>E. meningoseptica</i>	37	I	NG_048691
VIM	Verona integron-encoded MBL	1999	<i>P. aeruginosa</i>	78	A	NG_050336
IND	—	1999	<i>C. indologenes</i>	16	I	NG_049224
EBR	<i>Empedobacter brevis</i> MBL	2002	<i>E. brevis</i>	4	I	NG_049078
SPM	Sao Paulo MBL	2002	<i>P. aeruginosa</i>	1	A	NG_050140
CGB	—	2002	<i>C. gleum</i>	1	I	NG_051689
MUS	—	2002	<i>M. odoratimimus</i>	2	I	NG_049324
TUS	—	2002	<i>M. odoratus</i>	1	I	NG_050315
JOHN	—	2003	<i>F. johnsoniae</i>	1	I	NG_049239
GIM	German imipenemase	2004	<i>P. aeruginosa</i>	2	A	NG_049143
SIM	Seoul imipenemase	2005	<i>A. baumannii</i>	2	A	NG_050131
SLB	—	2005	<i>S. livingstonensis</i>	1	I	NG_047545
SFB	—	2005	<i>S. frigidimarina</i>	1	I	NG_047544
KHM	Kyorin Health Science MBL	2008	<i>C. freundii</i>	1	A	NG_049240
NDM	New Delhi MBL	2008	<i>K. pneumonia</i> , <i>E. coli</i>	43	A	NG_049326
ALI	<i>Aliivibrio salmonicida</i> MBL	2008	<i>A. salmonicida</i>	2	I	NG_057427
DIM	Dutch imipenemase	2010	<i>P. stutzeri</i>	1	A	NG_049077
FIM	Florence imipenemase	2012	<i>P. aeruginosa</i>	1	A	NG_049091
TMB	Tripoli MBL	2012	<i>A. xylosoxidans</i>	2	I	NG_050313
PEDO-3	—	2015	<i>P. kyungheensis</i>	1	I	NG_049959
ANA	—	2015	<i>Anaeromyxobacter</i> spp.	1	—	NG_057424
MOC	—	2016	<i>M. odoratus</i>	1	—	NG_051495
GRD23	—	2016	—	1	A	NG_062239
SPN79	—	2016	—	1	—	NG_062234
HMB	Hamburg MBL	2017	<i>P. aeruginosa</i>	1	I	NG_052225
VarG	—	2017	<i>V. cholerae</i>	1	I	NG_057468
ECV	—	2017	<i>E. vietnamensis</i>	1	—	NG_059320
FIA	—	2017	<i>F. aestuarina</i>	1	—	NG_057437
MYO	—	2017	<i>M. odoratimimus</i>	1	A	NG_059325
MYX	—	2017	<i>M. xanthus</i>	1	—	NG_057453
ORR	—	2017	<i>O. rhinotracheale</i>	1	I	NG_059317
PST	—	2017	<i>P. stutzeri</i>	2	—	NG_057439
SHD	—	2017	<i>S. denitrificans</i>	1	—	NG_077967
SHN	—	2017	<i>S. denitrificans</i>	1	—	NG_059313

SPS	—	2017	<i>S. smaragdinae</i>	1	—	NG_059316
STA	—	2017	<i>S. aurantiaca</i>	1	—	NG_057419
TTU	—	2017	<i>T. turnerae</i>	1	—	NG_059314
ZOG	—	2017	<i>Z. galactanivorans</i>	1	—	NG_057434
AFM	<i>Alcaligenes faecalis</i> MBL	2018	<i>A. faecalis</i>	4	A	NG_063835
CAM	Central Alberta MBL	2019	<i>P. aeruginosa</i>	1	A	NG_065859
VMB	<i>Vibrio</i> MBL	2020	<i>V. alginolyticus</i>	1	A	NG_070758
VAM	<i>Vibrio alginolyticus</i> MBL	2021	<i>V. alginolyticus</i>	1	A	NG_076653
GMB	German MBL	2022	<i>C. freundii</i> , <i>S. marcescens</i> , <i>R. planticola</i>	1	A	NG_073463
CrxA	Carbapenem resistance protein of <i>Bacteroides xylanisolvens</i>	2022	<i>B. xylanisolvens</i>	1	A	QPIO01000015
WUS	—	2022	<i>M. albus</i>	1	—	NG_080791
Subclass B2						
CphA	Carbapenemase hydrolysing <i>Aeromonas</i>	1991	<i>A. hydrophila</i>	12	I	NG_050396
ImiS	—	1996	<i>A. veronii</i>	1	I	NG_050415
ImiH	—	2003	<i>A. hydrophila</i>	1	I	NG_050414
Sfh	—	2003	<i>S. fonticola</i>	1	I	NG_052115
PFM	<i>Pseudomonas fluorescens</i> MBL	2019	<i>P. synxantha</i>	3	A	NG_065936
CVI	<i>Chromobacterium violaceum</i> MBL	2020	<i>C. violaceum</i>	1	—	NG_067986
YEM	<i>Yersinia</i> MBL	2020	<i>Y. mollaretii</i>	1	—	NG_070759
BioF	Biofilter	2022	<i>Psuedomonas</i> spp.	1	—	NZ_JACOMR010000005
Subclass B3						
L1	—	1982	<i>S. maltophilia</i>	17	I	NG_047506
FEZ	—	2000	<i>L. gormanii</i>	1	I	NG_049090
GOB	Class B β -lactamase of <i>C. meningosepticum</i>	2000	<i>E. meningoseptica</i>	52	I	NG_049145
THIN-B	—	2001	<i>J. lividum</i>	1	I	NG_047549
MBL1b	—	2001	<i>C. crescentus</i>	1	I	NG_049292
CAU	—	2002	<i>C. vibrioides</i>	1	I	NG_048755
BJP	—	2006	<i>B. japonicum</i>	2	I	NG_048709
CAR	—	2008	<i>E. carotovora</i>	1	I	NG_048712
LRA	β -lactam resistance from Alaskan soil	2009	<i>J. lividum</i>	8	—	NG_047519
POM	<i>Pseudomonas otitidis</i> MBL	2011	<i>P. otitidis</i>	2	I	NG_049974
SMB	<i>Serratia</i> MBL	2011	<i>S. marcescens</i>	1	A	NG_050133
AIM	Adelaide imipenemase	2012	<i>P. aeruginosa</i>	2	A	NG_048689
EAM	—	2012	<i>E. aquimaris</i>	1	I	NG_062208
ECM	—	2012	<i>E. citreus</i>	1	I	NG_062207

EFM	—	2012	<i>E. flavus</i>	1	I	NG_062204
ELM	—	2012	<i>E. longus</i>	1	I	NG_062206
EVM	—	2012	<i>E. vulgaris</i>	1	I	NG_062205
PAM	<i>Pseudomonas alcaligenes</i>	2013	<i>P. alcaligenes</i>	3	I	NG_076630
	MBL					
SPR	—	2014	<i>S. proteamaculans</i>	1	—	NG_052102
PEDO	—	2015	<i>P. roseu, P. borealis</i>	2	I	NG_049957
CPS	—	2015	<i>C. piscium</i>	1	I	NG_048587
ESP	—	2015	<i>E. tenax</i>	1	I	NG_049088
MSI	—	2015	<i>M. oculi</i>	1	I	NG_049323.
					2	
SPG	—	2015	<i>Sphingomonas</i> spp.	1	I	NG_050139
Rm3	—	2016	—	1	—	NG_052128
GRD33	—	2016	—	1	I	NG_062238
CRD3	—	2016	—	1	I	NG_062235
DHT2	—	2016	<i>S. maltophilia</i>	1	I	NG_062233
ALG6	—	2016	—	1	I	NG_062236
ALG11	—	2016	—	1	—	NG_062237
PLN	<i>Pedobacter lusitanus</i>	2017	<i>P. lusitanus</i>	1	—	NG_055471
PNGM	Papua New Guinea MBL	2018	—	1	—	NG_065937
LMB	Linz MBL	2018	<i>E. cloacae</i>	1	A	NG_070744
B3SU1	—	2021	—	1	—	NG_076657
B3SU2	—	2021	—	1	—	NG_076658
SIE	<i>Sphingobium indicum</i> B3-E	2021	<i>S. indicum</i>	1	—	NG_081773
	MBL					
NWM	—	2022	<i>P. aeruginosa</i>	1	—	NG_081702
PJM	<i>Pseudoxanthomonas</i>	2022	<i>P. japonensis</i>	1	—	NG_080789
	<i>japonensis</i> MBL					










^aMBL, metallo- β -lactamase.









^bSpecies: *A. baumannii*, *Acinetobacter baumannii*; *A. hydrophila*, *Aeromonas hydrophila*; *A. veronii*, *Aeromonas veronii*; *A. faecalis*, *Alcaligenes faecalis*; *A. salmonicida*, *Aliivibrio salmonicida*; *A. xylosoxidans*, *Achromobacter xylosoxidans*; *B. xylanisolvens*, *Bacteroides xylanisolvens*; *B. cereus*, *Bacillus cereus*; *B. fragilis*, *Bacteroides fragilis*; *B. japonicum*, *Bradyrhizobium japonicum*; *C. crescentus*, *Caulobacter crescentus*; *C. vibrioides*, *Caulobacter vibrioides*; *C. violaceum*, *Chromobacterium violaceum*; *C. gleum*, *Chryseobacterium gleum*; *C. indologenes*, *Chryseobacterium indologenes*; *C. piscium*, *Chryseobacterium piscium*; *C. freundii*, *Citrobacter freundii*; *E. meningoseptica*, *Elizabethkingia Meningoseptica*; *E. vietnamensis*, *Echinicola vietnamensis*; *E. brevis*, *Empedobacter brevis*; *E. cloacae*, *Enterobacter cloacae*; *E. tenax*, *Eristalis tenax*; *E. carotovora*, *Erwinia carotovora*; *E. aquimaris*, *Erythrobacter aquimaris*; *E. citreus*, *Erythrobacter citreus*; *E. flavus*, *Erythrobacter flavus*; *E. longus*, *Erythrobacter longus*; *E. vulgaris*, *Erythrobacter vulgaris*; *E. coli*, *Escherichia coli*; *F. aestuarina*, *Fibrella aestuarina*; *F. johnsoniae*, *Flavobacterium johnsoniae*; *J. lividum*, *Janthinobacterium lividum*; *K. pneumoniae*, *Klebsiella pneumoniae*; *L. gormanii*, *Legionella gormanii*; *M. oculi*, *Massilia*

oculi; *M. albus*, *Myroides albus*; *M. odoratimimus*, *Myroides odoratimimus*; *M. odoratus*, *Myroides odoratus*; *M. xanthus*, *Myxococcus xanthus*; *O. rhinotracheale*, *Ornithobacterium rhinotracheale*; *P. borealis*, *Pedobacter borealis*; *P. kyungheensis*, *Pedobacter kyungheensis*; *P. lusitanus*, *Pedobacter lusitanus*; *P. roseu*, *Pedobacter roseu*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *P. alcaligenes*, *Pseudomonas alcaligenes*; *P. otitidis*, *Pseudomonas otitidis*; *P. stutzeri*, *Pseudomonas stutzeri*; *P. synxantha*, *Pseudomonas synxantha*; *P. japonensis*, *Pseudoxanthomonas japonensis*; *R. planticola*, *Raoultella planticola*; *S. fonticola*, *Serratia fonticola*; *S. marcescens*, *Serratia marcescens*; *S. proteamaculans*, *Serratia proteamaculans*; *S. denitrificans*, *Shewanella denitrificans*; *S. frigidimarina*, *Shewanella frigidimarina*; *S. livingstonensis*, *Shewanella livingstonensis*; *S. indicum*, *Sphingobium indicum*; *S. smaragdinae*, *Spirochaeta smaragdinae*; *S. maltophilia*, *Stenotrophomonas maltophilia*; *S. aurantiaca*, *Stigmatella aurantiaca*; *T. turnerae*, *Teredinibacter turnerae*; *V. alginolyticus*, *Vibrio alginolyticus*; *V. cholerae*, *Vibrio cholerae*; *Y. mollaretii*, *Yersinia mollaretii*; *Z. galactanivorans*, *Zobellia galactanivorans*.










^cIntr./acq., intrinsic to the species or acquired (not intrinsic to the species).










Supplementary Table S2. Inhibitor types and representative MBL inhibitors with inhibitory data and inhibition modes.










Type ^a	Chemical Structure	Inhibition Mode	Inhibitory Data	Ref.
Type I		B1 IMP-1 (PDB ID 3WXC) 	B1 IMP-1 IC ₅₀ = 2.7 μM	[S1]
Type I		B1 VIM-2 (PDB ID 4PVT) 	B1 NDM-1 IC ₅₀ = 1.05 μM B1 VIM-1 IC ₅₀ = 0.44 μM B1 VIM-2 IC ₅₀ = 0.30 μM B1 SPM-1 IC ₅₀ = 1.76 μM B1 IMP-1 IC ₅₀ = 0.00288 μM B1 BclI IC ₅₀ = 0.02 μM	[S2]
Type I (partly like Type III)		B1 NDM-1 (PDB ID 6D1B) 	B1 NDM-1 K _i = 123.7 μM B1 VIM-2 K _i = 2.1 μM	[S3]
Type I		B1 NDM-1 (PDB ID 6KZL) 	B1 NDM-1 K _i = 9.08 μM B1 VIM-2 K _i = 0.42 μM B1 IMP-1 K _i = 1.23 μM	[S4]
Type I		B2 CphA N220G (PDB ID 3IOG)	B1 VIM-4 K _i = 1 μM B2 CphA K _i = 5 μM B3 L1 K _i = 0.40 μM	[S5]






				
Type I (partly like Type III)		B3 L1 (PDB ID 5HH6) 	B1 NDM-1 $K_i = 0.078 \mu\text{M}$ B1 VIM-2 $K_i = 0.61 \mu\text{M}$ B1 IMP-1 $K_i = 1.5 \mu\text{M}$ B3 L1 $K_i = 0.4 \mu\text{M}$	[S6]
Type I		B1 IMP-1 (PDB ID 1DD6) 	B1 IMP-1 $\text{IC}_{50} = 0.09 \mu\text{M}$	[S7]
Type I		B1 VIM-2 (PDB ID 5O7N) 	B1 NDM-1 $\text{IC}_{50} = 0.7 \mu\text{M}$ B1 VIM-1 $\text{IC}_{50} = 4.6 \mu\text{M}$ B1 IMP-7 $\text{IC}_{50} = 0.9 \mu\text{M}$	[S8]
Type I		B1 NDM-1 (PDB ID 4U4L)	B1 NDM-1 $K_i = 7 \mu\text{M}$ B1 VIM-2 $K_i = 2.9 \mu\text{M}$ B1 IMP-1 $K_i = 8 \mu\text{M}$ B1 BclI $K_i = 36 \mu\text{M}$ B2 Sfh-I $K_i = 0.26 \mu\text{M}$ B3 L1 $K_i = 12 \mu\text{M}$ B3 GOB-18 $K_i = 41 \mu\text{M}$	[S9]






Type I		B1 IMP-1 (PDB ID 4C1G) 	B1 NDM-1 IC_{50} = 20.1 μ M B1 VIM-2 IC_{50} = 0.072 μ M B1 IMP-1 IC_{50} = 7.2 μ M B1 SPM-1 IC_{50} = 261.8 μ M B1 BclI IC_{50} = 10.7 μ M	[S10]
Type I		B1 IMP-1 (PDB ID 1JJT) 	B1 IMP-1 IC_{50} = 0.009 μ M	[S11]
Type I		B3 L1 (PDB ID 2GFJ) 	B3 L1 IC_{50} = 150 μ M	[S12]
Type I		B3 L1 (PDB ID 2GFK) 	B3 L1 IC_{50} = 30 μ M	[S12]









				
Type I		B3 L1 (PDB ID 2FU9) 	B3 BclI K_i = 42 μM	[S12]
Type I		B1 VIM-2 (PDB ID 5N4S) 	B1 NDM-1 IC_{50} = 24.81 μM B1 VIM-1 IC_{50} = 0.526 μM B1 VIM-2 IC_{50} = 0.055 μM B1 VIM-5 IC_{50} = 0.175 μM B1 IMP-1 IC_{50} = 0.041 μM B1 SPM-1 IC_{50} = 0.89 μM B1 BclI IC_{50} = 1.63 μM B2 CphA IC_{50} ~ 400 μM B3 L1 IC_{50} = 16.21 μM	[S13]
Type I		B1 VIM-2 (PDB ID 5Y6D) 	B1 NDM-1 IC_{50} = 5.59 μM B1 VIM-2 IC_{50} = 0.055 μM	[S14]
Type I		B1 VIM-2 (PDB ID 6J8R) 	B1 NDM-1 IC_{50} = 67.13 μM B1 VIM-2 IC_{50} = 0.76 μM B3 GOB-18 IC_{50} = 2.23 μM	[S15]










				
Type I		B1 VIM-2 (PDB ID 6JN6) 	B1 NDM-1 IC ₅₀ = 6.06 μM B1 VIM-2 IC ₅₀ = 0.07 μM B3 GOB-18 IC ₅₀ = 10.98 μM	[S15]
Type I		B1 BcII (PDB ID 6F2N) 	B1 NDM-1 IC ₅₀ = 1.1 μM B1 VIM-2 IC ₅₀ = 0.1 μM B1 IMP-1 IC ₅₀ = 0.08 μM B1 SPM-1 IC ₅₀ = 0.06 μM B1 BcII IC ₅₀ = 0.2 μM	[S16]
Type I		B3 SMB-1 (PDB ID 3VQZ) 	B3 SMB-1 K _i = 9.4 μM	[S17]
Type I		B3 SMB-1 (PDB ID 5AXR) 	B3 SMB-1 K _i = 184 μM	[S18]










Type I		B3 SMB-1 (PDB ID 6K4X) 	B1 NDM-1 IC ₅₀ > 500 μM B1 VIM-2 IC ₅₀ = 42.1 μM B1 IMP-1 IC ₅₀ = 11.3 μM B3 SMB-1 IC ₅₀ = 0.22 μM B3 AIM-1 IC ₅₀ = 1.9 μM B3 L1 IC ₅₀ = 0.51 μM	[S19]
Type I		B1 VIM-2 (PDB ID 2YZ3) 	B1 VIM-2 K _i = 0.22 μM B1 IMP-1 K _i = 1.66 μM	[S20]
Type I		B1 VIM-2 (PDB ID 5K48) 	B1 NDM-1 IC ₅₀ = 5.59 μM B1 VIM-2 IC ₅₀ = 0.23 μM B1 IMP-1 IC ₅₀ = 0.23 μM	[S21]
Type I		B1 VIM-2 (PDB ID 6ZYN) 	B1 NDM-1 IC ₅₀ = 0.44 μM B1 VIM-2 IC ₅₀ = 0.75 μM B1 IMP-1 IC ₅₀ = 0.46 μM	[S22]
Type I		B1 IMP-1 (PDB ID 2DOO)	B1 IMP-1 K _i = 0.14 μM	[S23]









				
Type I		B1 VIM-2 (PDB ID 5MM9)	B1 NDM-1 IC ₅₀ = 1.8 μM B1 VIM-2 IC ₅₀ = 0.38 μM B1 GIM-1 IC ₅₀ = 0.31 μM	[S24]
Type I		B1 VIM-2 (PDB ID 5NHZ)	B1 NDM-1 IC ₅₀ = 1.8 μM B1 VIM-2 IC ₅₀ = 6.6 μM B1 GIM-1 IC ₅₀ = 26 μM	[S24]
Type I		B1 VIM-2 (PDB ID 7CJL)	B1 VIM-2 IC ₅₀ = 0.044 μM B1 NDM-1 IC ₅₀ = 0.396 μM B1 IMP-1 IC ₅₀ = 0.71 μM	[S25]
Type I		B1 VIM-2 (PDB ID 5ACW)	B1 VIM-2 IC ₅₀ = 232 μM	[S26]








Type I		B3 BJP-1 (PDB ID 5WCM)	B3 BJP-1 $K_i = 100 \mu\text{M}$	[S27]
Type I / Type III		B1 VIM-1 (PDB ID 7AYJ)	B1 NDM-1 $\text{pIC}_{50} = 8.1$ B1 VIM-1 $\text{pIC}_{50} = 6.9$ B1 VIM-2 $\text{pIC}_{50} = 7.7$ B1 IMP-1 $\text{pIC}_{50} = 9.2$	[S28]
Type I		B1 VIM-2 (PDB ID 6YRP)	B1 NDM-1 $K_i = 27 \mu\text{M}$ B1 VIM-2 $K_i = 0.7 \mu\text{M}$ B1 VIM-4 $K_i = 0.5 \mu\text{M}$ B2 CphA $K_i = 13 \mu\text{M}$ B3 L1 $K_i = 9 \mu\text{M}$	[S29]
Type I		B3 L1 (PDB ID 2HB9)	-	[S12]
Type I		B1 VIM-2 (PDB ID 7OVF)	B1 NDM-1 $K_i = 15.1 \mu\text{M}$ B1 VIM-1 $K_i = 2.22 \mu\text{M}$ B1 VIM-2 $K_i = 0.83 \mu\text{M}$ B1 VIM-4 $K_i = 1.11 \mu\text{M}$ B1 IMP-1 $K_i = 9.66 \mu\text{M}$	[S30]

				
Type I		B1 VIM-2 (PDB ID 6KW1) 	B1 VIM-2 IC ₅₀ = 58.6 μM	[S31]
Type II (partly like Type IV)		B1 NDM-7 (PDB ID 7AEZ) 	B1 NDM-1 pIC ₅₀ = 9.2 B1 VIM-2 pIC ₅₀ = 8 B1 IMP-1 pIC ₅₀ = 7.7	[S32]
Type II		B1 VIM-2 (PDB ID 5LE1) 	B1 VIM-2 IC ₅₀ = 10.6 μM	[S33]
Type II		B1 NDM-1 (PDB ID 6MDU)	B1 NDM-1 K _i = 56 μM	[S34]

				
Type III	 QPX-7728 (Phase I)	B1 NDM-1 (PDB ID 6V1M) 	B1 NDM-1 $K_i = 0.032 \mu\text{M}$ B1 VIM-1 $K_i = 0.008 \mu\text{M}$ B1 IMP-1 $K_i = 0.22 \mu\text{M}$	[S39]
Type III	 	B1 VIM-2 (PDB ID 6RPN) 	B1 NDM-1 $pIC_{50} = 7.4$ B1 VIM-1 $pIC_{50} = 7.1$ B1 VIM-2 $pIC_{50} = 7.2$ B1 IMP-1 $pIC_{50} = 6.9$ B2 CphA $pIC_{50} = 6.3$ B1 L1 $pIC_{50} = 5.3$	[S40]
Type III	 	B1 NDM-1 (PDB ID 6IBV) 	B1 NDM-1 $K_i = 5.9 \mu\text{M}$	[S41]
Type III	 	B1 SPM-1 (PDB ID 5NDB) 	B1 IMP-1 $IC_{50} = 213 \mu\text{M}$	[S42, 43]

Type IV	 ANT431	B1 VIM-2 (PDB ID 6HF5) 	B1 NDM-1 IC₅₀ = 2.67 μM B1 VIM-1 IC₅₀ > 200 μM B1 VIM-2 IC₅₀ = 6.7 μM B1 IMP-1 IC₅₀ = 54.0 μM	[S44]
Type IV	 	B1 VIM-2 (PDB ID 7CHV) 	B1 NDM-1 IC₅₀ = 66.7 μM B1 VIM-2 IC₅₀ = 0.45 μM B1 IMP-1 IC₅₀ = 15.2 μM	[S45]
Type IV	 	B1 IMP-1 (PDB ID 5HH4) 	B1 NDM-1 K_i = 0.07 μM B1 VIM-2 K_i = 0.54 μM B1 IMP-1 K_i = 1.1 μM B3 L1 K_i = 0.5 μM	[S6]
Type IV	 	B1 VIM-2 (PDB ID 5MXQ) 	B1 NDM-1 IC₅₀ = 49.9 μM B1 VIM-1 IC₅₀ > 200 μM B1 VIM-2 IC₅₀ = 1.9 μM B1 IMP-1 IC₅₀ > 200 μM	[S44]
Type IV	 	B2 CphA (PDB ID 2GKL)	B2 CphA IC₅₀ = 4.5 μM	[S46]

				
Type IV (partly like Type II)		B1 NDM-1 (PDB ID 6EFJ) 	B1 NDM-1 $K_i = 477 \mu\text{M}$	[S34]
Type V	 AMA	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $IC_{50} = 4.0 \mu\text{M}$ B1 VIM-2 $IC_{50} = 9.6 \mu\text{M}$	[S47]
Type V	 Dipicolinic Acid	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $IC_{50} = 0.08 \mu\text{M}$ B1 VIM-2 $IC_{50} = 0.21 \mu\text{M}$ B1 IMP-1 $IC_{50} = 0.24 \mu\text{M}$	[S48]
Type V	 EDTA	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 IMP-1 $IC_{50} = 27.9 \mu\text{M}$	[S49]
Type V	 EDDS	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $IC_{50} = 0.18 \mu\text{M}$ B1 VIM-1 $IC_{50} = 8 \mu\text{M}$ B1 SIM-1 $IC_{50} = 9 \mu\text{M}$	[S50]
Type V	 NOTA	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $K_i = 5.11 \mu\text{M}$	[S51]

Type V		Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $K_i = 5.63 \mu\text{M}$	[S51]
Type V	 SIT-Z5	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $\text{IC}_{50} = 6.6 \mu\text{M}$	[S52]
Type V	 H2dedpa	Removing active site zinc ions or sequestering zinc ions in bacterial environment	B1 NDM-1 $\text{IC}_{50} = 0.17 \mu\text{M}$	[S53]
Type V	 CBS	² Replacing active site zinc ions by one Bi(III) ion	B1 NDM-1 $\text{IC}_{50} = 2.81 \mu\text{M}$ B1 VIM-2 $\text{IC}_{50} = 3.55 \mu\text{M}$ B1 IMP-4 $\text{IC}_{50} = 0.70 \mu\text{M}$	[S54]
Type V	 Ebselen	Binding to NDM-1 by forming a S-Se bond with the residue C ₂₂₁ to destroy the active site	B1 NDM-1 $K_i = 0.38 \mu\text{M}$	[S55]
Type V	 SB214752	Inhibiting BclI by modifying the active site cysteine to destroy the active site	B1 BclI $\text{IC}_{50} = 645 \mu\text{M}$ B3 L1 $\text{IC}_{50} = 2 \mu\text{M}$	[S56]
Type V	 p-CMB	Inhibiting NDM-1 by modifying the active site cysteine to destroy the active site	B1 NDM-1 $\text{IC}_{50} = 9.0 \mu\text{M}$	[S57]

^a **Type I inhibitors:** replacing nucleophilic W₁ and W₂

Type II inhibitors: mimicking initial binding of intact β -lactams

Type III inhibitors: imitating the tetrahedral intermediates

Type IV inhibitors: simulating the binding of β -lactam anionic intermediates or hydrolysed products

Type V inhibitors: destructing active site metal binding

References

- S1. Hiraiwa, Y. *et al.* (2014) X-ray crystallographic analysis of IMP-1 metallo- β -lactamase complexed with a 3-aminophthalic acid derivative, structure-based drug design, and synthesis of 3,6-disubstituted phthalic acid derivative inhibitors. *Bioorganic Med. Chem. Lett.* 24, 4891-4894.
- S2. Brem, J. *et al.* (2014) Rhodanine hydrolysis leads to potent thioenolate mediated metallo- β -lactamase inhibition. *Nat. Chem.* 6, 1084-1090.
- S3. Pemberton, O.A. *et al.* (2019) Heteroaryl phosphonates as noncovalent inhibitors of both serine- and metallocarbapenemases. *J. Med. Chem.* 62, 8480-8496.
- S4. Wachino, J.-I. *et al.* (2020) Sulfamoyl heteroarylcarboxylic acids as promising metallo- β -lactamase inhibitors for controlling bacterial carbapenem resistance. *mBio* 11, e03144-19.
- S5. Lassaux, P. *et al.* (2010) Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo- β -lactamases. *J. Med. Chem.* 53, 4862-4876.
- S6. Hinchliffe, P. *et al.* (2018) Structural and kinetic studies of the potent inhibition of metallo- β -lactamases by 6-phosphonomethylpyridine-2-carboxylates. *Biochemistry* 57, 1880-1892.
- S7. Concha, N.O. *et al.* (2000) Crystal structure of the IMP-1 metallo β -lactamase from *Pseudomonas aeruginosa* and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. *Biochemistry* 39, 4288-4298.
- S8. Büttner, D. *et al.* (2018) Challenges in the development of a thiol-based broad-spectrum inhibitor for metallo- β -lactamases. *ACS Infect. Dis.* 4, 360-372.
- S9. Hinchliffe, P. *et al.* (2016) Cross-class metallo- β -lactamase inhibition by bisthiazolidines reveals multiple binding modes. *Proc. Natl. Acad. Sci. U. S. A.* 113, E3745-E3754.
- S10. Brem, J. *et al.* (2015) Structural basis of metallo- β -lactamase inhibition by captopril stereoisomers. *Antimicrob. Agents Chemother.* 60, 142-150.
- S11. Toney, J.H. *et al.* (2001) Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo- β -lactamase. *J. Biol. Chem.* 276, 31913-31918.

- S12. Nauton, L. *et al.* (2008) Structural insights into the design of inhibitors for the L1 metallo- β -lactamase from *Stenotrophomonas maltophilia*. *J. Mol. Biol.* 375, 257-269.
- S13. Li, G.-B. *et al.* (2017) Crystallographic analyses of isoquinoline complexes reveal a new mode of metallo- β -lactamase inhibition. *ChemComm* 53, 5806-5809.
- S14. Liu, S. *et al.* (2018) ((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo- β -lactamase inhibitors: synthesis, kinetic and crystallographic studies. *Eur. J. Med. Chem.* 145, 649-660.
- S15. Wang, Y.-L. *et al.* (2019) Structure-based development of (1-(3'-mercaptopropanamido)methyl)boronic acid derived broad-spectrum, dual-action inhibitors of metallo- and serine- β -lactamases. *J. Med. Chem.* 62, 7160-7184.
- S16. Zhang, D. *et al.* (2018) Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo- β -lactamases. *Bioorg. Med. Chem.* 26, 2928-2936.
- S17. Wachino, J.-i. *et al.* (2013) Structural insights into the subclass B3 metallo- β -lactamase SMB-1 and the mode of inhibition by the common metallo- β -lactamase inhibitor mercaptoacetate. *Antimicrob. Agents Chemother.* 57, 101-109.
- S18. Wachino, J.-i. *et al.* (2016) Structural insights into recognition of hydrolyzed carbapenems and inhibitors by subclass B3 metallo- β -lactamase SMB-1. *Antimicrob. Agents Chemother.* 60, 4274-4282.
- S19. Wachino, J.-i. *et al.* (2019) 4-Amino-2-sulfanylbzoic acid as a potent subclass B3 metallo- β -lactamase-specific inhibitor applicable for distinguishing metallo- β -lactamase subclasses. *Antimicrob. Agents Chemother.* 63, e01197-19.
- S20. Yamaguchi, Y. *et al.* (2007) Crystallographic investigation of the inhibition mode of a VIM-2 metallo- β -lactamase from *Pseudomonas aeruginosa* by a mercaptocarboxylate inhibitor. *J. Med. Chem.* 50, 6647-6653.
- S21. Cain, R. *et al.* (2018) *In silico* fragment-based design identifies subfamily B1 metallo- β -lactamase inhibitors. *J. Med. Chem.* 61, 1255-1260.
- S22. Rossi, M.-A. *et al.* (2021) 2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo- β -lactamases. *Chem. Sci.* 12, 2898-2908.

- S23. Kurosaki, H. *et al.* (2006) Probing, inhibition, and crystallographic characterization of metallo- β -lactamase (IMP-1) with fluorescent agents containing dansyl and thiol groups. *ChemMedChem* 1, 969-972.
- S24. Skagseth, S. *et al.* (2017) Metallo- β -lactamase inhibitors by bioisosteric replacement: preparation, activity and binding. *Eur. J. Med. Chem.* 135, 159-173.
- S25. Yan, Y.-H. *et al.* (2020) Discovery of mercaptopropanamide-substituted aryl tetrazoles as new broad-spectrum metallo- β -lactamase inhibitors. *RSC Adv.* 10, 31377-31384.
- S26. Christopeit, T. *et al.* (2015) Discovery of novel inhibitor scaffolds against the metallo- β -lactamase VIM-2 by surface plasmon resonance (SPR) based fragment screening. *J. Med. Chem.* 58, 8671-8682.
- S27. Docquier, J.-D. *et al.* (2010) High-resolution crystal structure of the subclass B3 metallo- β -lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. *Antimicrob. Agents Chemother.* 54, 4343-4351.
- S28. Farley, A.J.M. *et al.* (2021) Structural basis of metallo- β -lactamase inhibition by N-sulfamoylpyrrole-2-carboxylates. *ACS Infect. Dis.* 7, 1809-1817.
- S29. Gavara, L. *et al.* (2020) 4-Amino-1,2,4-triazole-3-thione-derived schiff bases as metallo- β -lactamase inhibitors. *Eur. J. Med. Chem.* 208, 112720.
- S30. Legru, A. *et al.* (2021) 1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are broad-spectrum metallo- β -lactamase inhibitors with re-sensitization activity. *Eur. J. Med. Chem.* 226, 113873.
- S31. Xiang, Y. *et al.* (2020) Kinetic, thermodynamic, and crystallographic studies of 2-triazolylthioacetamides as Verona integron-encoded metallo- β -lactamase 2 (VIM-2) Inhibitor. *Biomolecules* 10, 72.
- S32. Brem, J. *et al.* (2022) Imitation of β -lactam binding enables broad-spectrum metallo- β -lactamase inhibitors. *Nat. Chem.* 14, 15-24.
- S33. Li, G.-B. *et al.* (2017) NMR-filtered virtual screening leads to non-metal chelating metallo- β -lactamase inhibitors. *Chem. Sci.* 8, 928-937.
- S34. Torelli, N.J. *et al.* (2019) Active-site druggability of carbapenemases and broad-spectrum inhibitor discovery. *ACS Infect. Dis.* 5, 1013-1021.

- S35. Muhammad, Z. *et al.* (2020) Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo- β -lactamases. *Bioorg. Med. Chem.* 28, 115598.
- S36. Payne David, J. *et al.* (2002) Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo- β -lactamases. *Antimicrob. Agents Chemother.* 46, 1880-1886.
- S37. Toney, J.H. *et al.* (1998) Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of *Bacteroides fragilis* metallo- β -lactamase. *Chem. Biol.* 5, 185-196.
- S38. Liu, B. *et al.* (2020) Discovery of Taniborbactam (VNRX-5133): A broad-spectrum serine- and metallo- β -lactamase inhibitor for carbapenem-resistant bacterial infections. *J. Med. Chem.* 63, 2789-2801.
- S39. Hecker, S.J. *et al.* (2020) Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo- β -lactamases. *J. Med. Chem.* 63, 7491-7507.
- S40. Parkova, A. *et al.* (2020) Broad spectrum β -lactamase inhibition by a thioether substituted bicyclic boronate. *ACS Infect. Dis.* 6, 1398-1404.
- S41. Cendron, L. *et al.* (2019) X-ray crystallography deciphers the activity of broad-spectrum boronic acid β -lactamase inhibitors. *ACS Medicinal Chem. Lett.* 10, 650-655.
- S42. Abboud, M.I. *et al.* (2018) Cyclobutanone mimics of intermediates in metallo- β -lactamase catalysis. *Chem. Eur. J.* 24, 5734-5737.
- S43. Johnson, J.W. *et al.* (2010) Cyclobutanone analogues of β -lactams revisited: insights into conformational requirements for inhibition of serine- and metallo- β -lactamases. *J. Am. Chem. Soc.* 132, 2558-2560.
- S44. Leiris, S. *et al.* (2019) SAR studies leading to the identification of a novel series of metallo- β -lactamase inhibitors for the treatment of carbapenem-resistant *Enterobacteriaceae* infections that display efficacy in an animal infection model. *ACS Infect. Dis.* 5, 131-140.
- S45. Dai, Q. *et al.* (2021) AncPhore: a versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo- β -lactamases and indoleamine/tryptophan 2,3-dioxygenases. *Acta Pharm. Sin. B* 11, 1931-1946.

- S46. Horsfall, L.E. *et al.* (2007) Competitive inhibitors of the CphA metallo- β -lactamase from *Aeromonas hydrophila*. *Antimicrob. Agents Chemother.* 51, 2136-2142.
- S47. King, A.M. *et al.* (2014) Aspergillomarasmine A overcomes metallo- β -lactamase antibiotic resistance. *Nature* 510, 503-506.
- S48. Chen, A.Y. *et al.* (2017) Dipicolinic acid derivatives as inhibitors of New Delhi metallo- β -lactamase-1. *J. Med. Chem.* 60, 7267-7283.
- S49. Chen, P. *et al.* (2012) 2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo- β -lactamases. *Bioorg. Med. Chem. Lett.* 22, 6229-6232.
- S50. Proschak, A. *et al.* (2018) Bacterial zincophore [S,S]-ethylenediamine-N,N'-disuccinic acid is an effective inhibitor of MBLs. *J. Antimicrob. Chemother.* 73, 425-430.
- S51. Zhang, E. *et al.* (2018) NOTA analogue: a first dithiocarbamate inhibitor of metallo- β -lactamases. *Bioorg. Med. Chem. Lett.* 28, 214-221.
- S52. Falconer, S.B. *et al.* (2015) Zinc chelation by a small-molecule adjuvant potentiates meropenem activity *in vivo* against NDM-1-producing *Klebsiella pneumoniae*. *ACS Infect. Dis.* 1, 533-543.
- S53. Shi, X.-F. *et al.* (2019) H₂depda: an acyclic adjuvant potentiates meropenem activity *in vitro* against metallo- β -lactamase-producing Enterobacterales. *Eur. J. Med. Chem.* 167, 367-376.
- S54. Wang, R. *et al.* (2018) Bismuth antimicrobial drugs serve as broad-spectrum metallo- β -lactamase inhibitors. *Nat. Commun.* 9, 439.
- S55. Chiou, J. *et al.* (2015) Ebselen as a potent covalent inhibitor of New Delhi metallo- β -lactamase (NDM-1). *ChemComm* 51, 9543-9546.
- S56. Payne, D.J. *et al.* (1997) Inhibition of metallo- β -lactamases by a series of mercaptoacetic acid thiol ester derivatives. *Antimicrob. Agents Chemother.* 41, 135-140.
- S57. Thomas, P.W. *et al.* (2013) An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo- β -lactamase-1 (NDM-1) discovered by high-throughput screening. *Bioorg. Med. Chem.* 21, 3138-3146.